The effects of vigabatrin on electrophysiology and visual fields in epileptics: A controlled study with a discussion of possible mechanisms

被引:29
作者
Comaish I.F. [1 ]
Gorman C. [1 ]
Brimlow G.M. [2 ]
Barber C. [2 ]
Orr G.M. [1 ]
Galloway N.R. [1 ]
机构
[1] Department of Ophthalmology, Queen's Medical Centre, Nottingham
[2] Department of Medical Physics, Queen's Medical Centre, Nottingham
关键词
Electrophysiology; Lateral inhibition; Oscillatory potentials; Vigabatrin; Visual fields;
D O I
10.1023/A:1014603229383
中图分类号
学科分类号
摘要
Purpose: To compare the visual electrophysiology and visual fields of patients taking vigabatrin to those of a control group of epileptics on other anti-epileptic drugs (AEDs). Methods: Fourteen epileptics treated with vigabatrin and 10 control patients treated with other AEDs underwent ERG and EOG. Goldmann visual fields were performed and analysed using standard software to measure areas contained within I4e isopters. Results: The cone and rod b-waves of the ERG, the oscillatory potential amplitudes and Arden indices were reduced in vigabatrin-treated subjects and the oscillatory potentials delayed. The Arden indices were reduced due to an increased dark trough. The areas contained within the I4e isopter of vigabatrin treated subjects were reduced compared to the control group and these areas correlated well with oscillatory potential amplitudes and b-wave amplitudes in the vigabatrin group only. Conclusions: The use of vigabatrin is associated with a reduction of the ERG cone b-wave amplitude and oscillatory potentials which correlates with visual field loss. The Arden ratio is reduced in subjects taking vigabatrin but may recover after cessation. However, visual loss may persist in the presence of a recovered EOG. These findings suggest further effects of the drug than those mediated by GABA receptors, and support the contention that the cause of the field loss may be at least in part due to retinal effects. Possible mechanisms are discussed.
引用
收藏
页码:195 / 212
页数:17
相关论文
共 70 条
[31]  
Vaquero C.F., De La Villa P., Localisation of the GABA(C) receptors at the axon terminal of the rod bipolar cells of the mouse retina, Neurosci Res, 35, 1, pp. 1-7, (1999)
[32]  
Krauss G.L., Johnson M.A., Miller N.R., Vigabatrin-associated retinal cone system dysfunction, Neurology, 50, 3, pp. 614-618, (1998)
[33]  
Arndt C.F., Derambure P., Defoort-Dhellemmes S., Hache J.C., Outer retinal dysfunction in patients treated with vigabatrin, Neurology, 52, 6, pp. 1201-1205, (1999)
[34]  
John R.A., Rimmer E.M., Williams J., Cole G., Fowler L.J., Richens A., Microvacuolation in rat brains after long term administration of GABA-transaminase inhibitors, Biochem Pharmacol, 36, 9, pp. 1467-1473, (1987)
[35]  
Schechter P.J., Clinical pharmacology of vigabatrin, Br J Clin Pharmacol, 27, SUPPL. 1, (1989)
[36]  
Gibson K.M., Nyhan W.L., Jaeken J., Inborn errors of GABA metabolism, Bioessays, 4, pp. 24-27, (1986)
[37]  
Vallat C., Rivier F., Bellet H., Magnan De Bornier B., Mion H., Echenne B., Treatment with vigabatrin may mimic alpha-aminoadipic aciduria, Epilepsia, 37, 8, pp. 803-805, (1996)
[38]  
Garner C.D., Lee E.W., Louis-Ferdinand R.T., Muller cell involvement in methanol-induced retinal toxicity, Toxicity Appl Pharmacol, 30, 1, pp. 101-107, (1995)
[39]  
Sherif F.M., Tawati A.M., Ahmed S.S., Sharif S.I., Basic aspects of GABA-transmission in alcoholism, with particular reference to GABA-transaminase, Eur Neuropsychopharmacol, 7, 1, pp. 1-7, (1997)
[40]  
Haugstad T.S., Langmoen I.A., L-alpha-aminoadipate reduces glutamate release from brain tissue exposed to combined oxygen and glucose deprivation, J Cereb Blood Flow Metab, 17, 5, pp. 567-570, (1997)